SCHEMBL969221

SCHEMBL969221

CCNC(=O)N(CC)CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
GAA P10253 1/20 0.43
LMNA P02545 1/20 0.40
MMP1 P03956 2/20 0.39
MMP2 P08253 2/20 0.39
MMP3 P08254 2/20 0.39
MMP8 P22894 2/20 0.39
MMP9 P14780 1/20 0.39
KMT2A Q03164 2/20 0.37
ABCC1 P33527 2/20 0.36
MCL1 Q07820 1/20 0.36
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP3A4 P08684 1/20 0.35
FAAH O00519 1/20 0.34
ALDH2 P05091 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3934067 1.00 ALDH1A1 (0.43) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL9475754 0.90 ALDH1A1 (0.41) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL1416281 0.85 ALDH1A1 (0.38) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL968823 0.85 CA12 (0.43) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL7765563 0.84 ALDH1A1 (0.42) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL9475748 0.83 LMNA (0.40) ALDH1A1LMNAMMP1MMP2MMP3
SCHEMBL11832724 0.82 ALDH1A1 (0.36) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL965270 0.82 CA12 (0.53) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL965052 0.82 CA12 (0.43) ALDH1A1GAALMNAMMP1MMP2
SCHEMBL11290100 0.81 ALDH1A1 (0.42) ALDH1A1GAAMMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809565-B2 Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of ureas or thioureas DSM IP ASSETS B.V. (NL) 2017-11-07 US claimed
EP-1862198-B1 Brightening and/or dyeing agent with urea derivatives HENKEL AG & CO KGAA (DE) 2017-04-05 EP claimed
EP-3016941-B1 FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF UREAS OR THIOUREAS DSM IP ASSETS BV (NL) 2017-03-22 EP claimed
US-20160145228-A1 FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF UREAS OR THIOUREAS DSM IP ASSETS B.V. (NL) 2016-05-26 US claimed
CN-105358540-A Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of ureas or thioureas DSM IP ASSETS BV 2016-02-24 CN claimed
EP-0331052-A2 Process for the preparation of imidized acrylic polymers ELF ATOCHEM ITALIA S.r.l. (IT) 1989-09-06 EP claimed
US-20250368836-A1 Polymer Thick Film Positive Temperature Coefficient Carbon Resistor Composition CELANESE MERCURY HOLDINGS INC (US) 2025-12-04 US disclosed
US-12351580-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC. (US) 2025-07-08 US disclosed
CN-119895628-A Solvent and method for recycling fluids 南洋理工大学 2025-04-25 CN disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
US-20240067649-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2024-02-29 US disclosed
US-11827632-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2023-11-28 US disclosed
US-5459147-A Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma DR. KARL THOMAE GMBH (DE) 1995-10-17 US disclosed
US-5308743-A USED IN THE MANUFACTURE OF SEMICONDUCTORS AND ELECTRONIC DEVICES FUJI PHOTO FILM CO., LTD. (JP) 1994-05-03 US disclosed
CN-1083812-A Benzimidazoles contains the pharmaceutical composition of these compounds and their preparation KRAL THOMAE GMBH (DE) 1994-03-16 CN disclosed
US-5284745-A Ripening, chemical sensitization under limited pH; rapid processing, latent-image stability, high contrast and sensitivity FUJI PHOTO FILM CO., LTD. (JP) 1994-02-08 US disclosed
US-5200310-A Rapid processing, high sensitivity, good in safelight aptitude, wear resistance, pressure resistance FUJI PHOTO FILM CO., LTD. (JP) 1993-04-06 US disclosed
EP-0495659-A1 A method for forming a dye image KONICA CORPORATION (JP) 1992-07-22 EP disclosed
US-4014876-A HYPOGLYCEMIC SHIONOGI & CO., LTD. (JA) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827632-B2 NLRP3 modulators NLRP3, NLRP1, NOD1 ALDH1A1 3584/4885GAA 3068/4885LMNA 3180/4885
US-20160145228-A1 FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF UREAS OR THIOUREAS UCK2, UMPS, HCCS ALDH1A1 1356/4885GAA 3528/4885LMNA 4434/4885
US-12351580-B2 NLRP3 modulators NLRP3, NLRP1, NOD1 ALDH1A1 3584/4885GAA 3068/4885LMNA 3180/4885
US-20240067649-A1 NLRP3 MODULATORS NLRP3, NLRP1, NOD1 ALDH1A1 3584/4885GAA 3068/4885LMNA 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.